Vascular smooth muscle cell activation by C-reactive protein

Cardiovascular Research

Volumn 58, Issue 1, 2003, Pages 186-195

  Hattori, Yoshiyuki ^a   Matsumura, Michiko ^a   Kasai, Kikuo ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Gene expression; Infection inflammation; Nitric oxide; Signal transduction; Smooth muscle

Indexed keywords

15 DEOXY 12,14 PROSTAGLANDIN J2; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; C REACTIVE PROTEIN; CERIVASTATIN; FLUINDOSTATIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROSTAGLANDIN DERIVATIVE; PROTEIN C FOS; PROTEIN C JUN; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; WY 14649;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ACTIVATION; CONTROLLED STUDY; EARLY RESPONSE GENE; ENZYME ACTIVATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; NONHUMAN; NORTHERN BLOTTING; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN INDUCTION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANALYSIS OF VARIANCE; ANIMALS; C-REACTIVE PROTEIN; CELLS, CULTURED; CHEMOKINE CCL2; ENZYME ACTIVATION; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; INDOLES; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS;

EID: 0037401072     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00855-6     Document Type: Article

References (43)

1. Ross R. Atherosclerosis - an inflammatory disease. New Engl J Med. 340:1999;115-126.
2. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New Engl J Med. 331:1994;417-424.
3. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 349:1997;462-466.
4. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med. 336:1997;973-979.
5. Koenig W., Sund M., Frohlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:1999;237-242.
6. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 101:2000;235-238.
7. Pasceri V., Cheng J.S., Willerson J.T., Yeh E.T., Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 103:2001;2531-2534.
8. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 103:2001;1194-1197.
9. Chamley-Campbell J., Campbell G.R., Ross R. The smooth muscle cell in culture. Physiol Rev. 59:1979;1-61.
10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
11. Hattori Y., Banba N., Gross S.S., Kasai K. Glycated serum albumin-induced nitric oxide production in vascular smooth muscle cells by nuclear factor kappaB-dependent transcriptional activation of inducible nitric oxide synthase. Biochem Biophys Res Commun. 259:1999;128-132.
12. Hattori Y., Akimoto K., Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun. 273:2000;1144-1149.
13. Schreiber E., Matthias P., Muller M.M., Schaffner W. Rapid detection of octamer proteins with mini-extracts, prepared from a small number of cells. Nucleic Acids Res. 17:1989;6419.
14. Hattori Y., Suzuki M., Hattori S., Kasai K. Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension. 39:2002;22-28.
15. Gross S.S., Levi R. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem. 267:1992;25722-25729.
16. Edgington T. More cellular signals for atherogenesis? Circulation. 98:1998;1151-1152.
17. Bourcier T., Sukhova G., Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem. 272:1997;15817-15824.
18. Brand K., Page S., Walli A.K., Neumeier D., Baeuerle P.A. Role of nuclear factor-kappa B in atherogenesis. Exp Phys. 82:1997;297-304.
19. Nelken N.A., Coughlin S.R., Gordon D., Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 88:1991;1121-1127.
20. Takeya M., Yoshimura T., Leonard E.J., Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol. 24:1993;534-539.
21. Akira S., Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev. 127:1992;25-50.
22. Loppnow H., Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 85:1990;731-738.
23. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:1992;3051-3064.
24. Lowenstein C.J., Snyder S.H. Nitric oxide, a novel biologic messenger. Cell. 70:1992;705-707.
25. Moncada S., Higgs E.A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9:1995;1319-1330.
26. Cooke J.P., Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 48:1997;489-509.
27. Darley-Usmar V.M., Hogg N., O'Leary V.J., Wilson M.T., Moncada S. The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic Res Commun. 17:1992;9-20.
28. Graham A., Hogg N., Kalyanaraman B., et al. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett. 330:1993;181-185.
29. White C.R., Brock T.A., Chang L.Y., et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA. 91:1994;1044-1048.
30. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 87:1990;1620-1624.
31. Ischiropoulos H., Zhu L., Beckman J.S. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys. 298:1992;446-451.
32. Libby P., Hansson G.K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 64:1991;5-15.
33. Arcoleo F., Milano S., D'Agostino P., Misiano G., Cappelletti S., Gromo G., Marcucci F., Leoni F., Cillari E. Effect of partially modified retro-inverso analogues derived from C-reactive protein on the induction of nitric oxide synthesis in peritoneal macrophages. Br J Pharmacol. 120:1997;1383-1389.
34. Ratnam S., Mookerjea S. The regulation of superoxide generation and nitric oxide synthesis by C-reactive protein. Immunology. 94:1998;560-568.
35. Ikeda U., Maeda Y., Yamamoto K., Shimada K. C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc Res. 56:2002;86-92.
36. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 100:1999;230-235.
37. Ortego M., Bustos C., Hernandez-Presa M.A., et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 147:1999;253-261.
38. Bustos C., Hernandez-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 32:1998;2057-2064.
39. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 101:2000;235-238.
40. Li A.C., Brown K.K., Silvestre M.J., et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 106:2000;523-531.
41. Jackson S.M., Parhami F., Xi X.P., et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 19:1999;2094-2104.
42. Marx N., Sukhova G.K., Collins T., Libby P., Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 99:1999;3125-3131.
43. de Beer F.C., Baltz M.L., Munn E.A., Feinstein A., Taylor J., Bruton C., Clamp J.R., Pepys M.B. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology. 45:1982;55-70.